Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio, Inc.

Passage Bio is a genetic medicines company focused on developing treatments for patients with neurodegenerative diseases. The company aims to deliver genetic medicines that will permanently redefine the course of these conditions.

Passage Bio

We are a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. 

Our lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. Our team's unwavering commitment to excellence is the driving force behind our mission to protect patients and their families against loss in neurodegenerative conditions.

Versant Ventures

New Leaf Venture Partners

Boxer Capital

OrbiMed

Lilly Asia Ventures

Logos Capital

Sphera Funds Management

Access Biotechnology

Frazier Healthcare Partners

Highline Capital Management

Len Blavatnik

We are pleased to announce the out-licensing of our pediatric lysosomal storage disease programs to Gemma Biotherapeutics, a new company founded by James M. Wilson, M.D., Ph.D., that is committed to advancing promising gene therapies for children with #GM1, #Krabbe, and #MLD. This strategic move extends our cash runway, enabling us to continue our vital work in adult neurodegenerative diseases.

Additionally, Passage Bio will launch a new research partnership with Gemma Biotherapeutics that will leverage our combined expertise to explore new frontiers in CNS research. Read more here: https://loom.ly/EC6p40I

Did you know progranulin is vital for brain cell health, and increasing its levels could benefit patients with both FTD-C9orf72 and FTD-GRN? Thanks to positive FDA feedback, we are expanding our upliFT-D trial to include individuals with C9orf72 gene mutations, marking a major milestone in treatment access. Learn more about this exciting news here: https://loom.ly/qMRn2rw

ICYMI: @Biotech TV recently joined us at our Philadelphia HQ to discuss our groundbreaking work in treating #FTD. Watch the full video to learn about what's on the horizon for Passage Bio here: https://loom.ly/4KgAgjc

This morning, we announced our second quarter 2024 #financialresults and recent #business highlights. It has been a pivotal quarter for Passage Bio, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs.

Learn more about our latest achievements and upcoming milestones here: https://loom.ly/HxgqpDQ

Passage Bio will be participating in the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13 and the 15th Annual Wedbush PacGrow Healthcare Conference in New York City on August 14. Our leadership team is eager to present our latest corporate updates and upcoming milestones. Discover more about our presence and what to expect here: https://loom.ly/NQfz__U

Did you know that Progranulin (PGRN) could unlock breakthroughs in the treatment of neurodegenerative diseases? At Passage Bio, we are exploring the therapeutic potential of elevating PGRN levels in the central nervous system to alter the course of neurodegenerative diseases. Discover more here: https://loom.ly/GtdTEMQ

If you or a loved one has #FTD, genetic counseling and testing are essential. It can pinpoint if a mutation caused your FTD, provide insights into your symptoms, and identify clinical trial eligibility, such as the upliFT-D trial for FTD-GRN. InformedDNA offers free genetic testing and counseling for US residents. Learn more here: https://loom.ly/hm5g0lc

We are thrilled to share that Passage Bio has received positive feedback from the FDA on expanding our upliFT-D trial of PBFT02 to include patients with frontotemporal dementia (#FTD) due to C9orf72 gene mutations. This expansion is a significant milestone in our mission to improve the lives of patients with neurodegenerative diseases. Read more here: https://lnkd.in/eQpgQsVD

It was an honor to have BiotechTV come visit our Philadelphia headquarters and discuss exciting milestones on the horizon for Passage!

Check out our recent podcast appearance! Our CEO Will Chou, MD, recently joined the Life Science Success Podcast to share updates from our ongoing clinical study for #FTD, the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families. 

Tune in for insights here: https://loom.ly/XCh2t9E #LifeScienceSuccess

NASDAQ:PASG

Passage Bio

Last Close

0.65

12/11 19:44

Market Cap

50.62M

Beta: 0.99

Volume Today

100.99K

Avg: 163.19K

PE Ratio

−0.50

PFCF: −0.66